Loading company…
Slate Bio develops T regulatory therapies for autoimmune diseases.
Slate Bio is developing T regulatory therapies intended to restore immune balance and address autoimmune diseases. The company is based in Charlottesville, US, and raised USD 1.35 mn in Seed funding in December 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in